Taking into consideration that in some IBD patients CRP levels remain within the normal range despite ongoing intestinal inflammation, galectin-3 measurements may offer greater benefit in evaluating proper response to biological treatment in IBD. The gene discussed is LGALS3; the disease is inflammatory bowel disease.